Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Q203 (Telacebec) in Healthy Volunteers
NCT02858973Phase 1Completed
- Sponsor
- Qurient Co., Ltd.
- Start
- Aug 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tuberculosis (TB) comparing Q203 with Placebo (2 arms). Primary endpoint: Safety assessment through adverse event, vital signs, ECG, laboratory results, and telemetry monitoring. Started Aug 2016; status: completed.
02
Drugs
Telacebec
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02858973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858973.